These test have been completed before too. 'Platform expansions' and this is very very very interesting timing. SB has tested Palmer before not under Sofdra formulation.
There have been a few studies exploring its application in other areas: Palmoplantar Hyperhidrosis: A retrospective case study investigated the efficacy of a 5% sofpironium bromide gel in treating palmoplantar hyperhidrosis (excessive sweating of the palms and soles) in patients with advanced Duchenne muscular dystrophy. The study reported a significant reduction in sweat production in the treated areas, with no serious adverse events observed.
Clozapine-Induced Hypersalivation: Research has been conducted on the use of sofpironium bromide gel for clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia. A double-blind, controlled crossover study demonstrated that the gel significantly reduced saliva production, suggesting potential off-label applications beyond hyperhidrosis. It's important to note that these studies utilized a 5% formulation of sofpironium bromide, which differs from the 12.45% concentration found in Sofdra.
(note for new comers: Sofdra's FDA approval is specifically for underarm use and it 12.5% formulation)
BOT Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)